Bioceres Crop Solutions Corp. financial statements

Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Bioceres Crop Solutions Corp. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	41.2	134	161	173	210	335	420	465	335
Cost of revenue	30.6	77.1	87	93.6	119	208	235	278	203
Gross profit	10.6	56.4	73.6	79.5	90.9	126	185	187	132
Research and development	0.85	3.95	3.69	4.2	5.62	6.95	15.3	17.2	14.9
Selling, general and administrative	8.83	35.3	39.2	38.3	47.6	77.5	113	124	123
General and administrative	0.17	0.57	0.38	0.36	0.68
Operating income	0.21	15.7	32.1	39.1	38.4	39.9	54.2	45.9	-2.24
Interest expense	7.15	17.2	23.4	20.9	21.2	17.9	23.8	26.9	28.8
Interest income	0.16	1.27	8.72
Pre-tax income	-8.04	-25.2	-9.37	6.44	10.5	14.1	19.1	11.1	-57.6
Income tax	-1.86	-10.9	6.99	2.21	14.4	18	-1.07	3.78	1.27
Net income to minority interests	-0.32	-3.27	2.01	0.88	3.05	3.29	1.39	3.01	-3.43
Net income	-5.87	-11	-18.4	3.36	-6.87	-7.2	18.8	4.28	-55.4
EPS, basic	-0.21	-0.39	-0.60	0.09	-0.18	-0.17	0.30	0.07	-0.88
EPS, diluted	-0.21	-0.39	-0.60	0.09	-0.18	-0.17	0.30	0.07	-0.88

Balance sheet

	FY2016	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents		2.22	3.45	42.5	36	33.5	48.1	44.5	32.7
Receivables		52.9	59.2	73.5	88.8	112	158	207
Inventory		19.4	27.3	29.3	61	126	140	126	87.6
Total current assets		85.3	98.2	165	211	298	397	409	308
Property, plant and equipment	46.4	40.2	43.8	41.5	48	49.9	67.9	74.6	74.6
Lease right-of-use assets				1.11	1.33	12.1	13.9	11.6	16.4
Goodwill		14.4	29.8	25.5	28.8	36.1	112	112	112
Intangible assets	42.4	26.7	39.6	35.3	67.3	76.7	174	177	181
Total assets		197	242	298	395	518	818	853	764
Accounts payable		27.7	40.6	57.3	72.1	126	151	169	96.4
Short-term debt		65.3	66.5	63.7	76.8	71.3	108	137	120
Total current liabilities		119	116	131	168	223	299	329	338
Lease liabilities				0.44	0.39	10.3	10	8.16	9.53
Total liabilities		164	180	237	304	360	488	501	468
Total debt				10.4
Shareholders' equity		13.7	47.3	46.2	67.7	127	299	315	265
Minority interests		19.4	14.8	14.6	22.5	30.9	31.9	36.3	29.8
Total equity	83.7	33.1	62.1	60.7	90.3	158	330	351	295
Total liabilities and equity		197	242	298	395	518	818	853	764

Cash flow statement

	FY2016	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-6.18	-14.3	-16.4	4.24	-3.82	-3.91	20.2	7.29	-58.8
Cash from operations	-1.22	18.4	29.7	9.32	-6.21	-17.5	2.59	41.7	49.9
Capital expenditures	-0.61	-2.79	-2.04	-1.65	-2.81	-3.46	-11.4	-9.79	-5.64
Cash from investing	-41.9	-8.22	-3.26	-7.8	-8.31	2.9	-25.7	-28.7	-6.13
Debt issued	10.5	27.7	88.7	135	143	140	79.8	136	266
Debt repaid	-6.35	-37.6	-111	-101	-113	-111	-16.7	-113	-288
Share buybacks				-0.03	-3.5		-3	-0.73	-0.93
Dividends paid	-0.01						-0.45	-0.17	-0.07
Cash from financing	44	-10.5	-26.9	33.5	7.36	14.8	33	-10.1	-50.7
Exchange rate effect	0.09	0.83	0.07	4.58	6.27	6.84	4.94	-6.56	-4.85
Free cash flow	-1.83	15.6	27.7	7.67	-9.01	-21	-8.77	31.9	44.3

Key metrics

Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $0.37 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	39.3%	Gross profit / revenue.
Operating margin	-0.7%	Operating income / revenue.
Pre-tax margin	-17.2%	Pre-tax income / revenue.
Net margin	-16.5%	Net income / revenue.
FCF margin	13.2%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	14.9%	Cash from operations / revenue.
Return on equity (ROE)	-19.1%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-6.9%	Net income / average total assets.
Return on invested capital (ROIC)	-0.7%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	4.5%	Research and development expense / revenue.
SG&A / revenue	36.7%	Selling, general and administrative expense / revenue.
Capex / revenue	1.7%	Capital expenditures / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-27.9%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	0.0%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	14.1%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-29.4%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	1.4%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	10.6%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	-104.9%	Operating income vs the same period a year earlier. Only from a positive base.
Net income growth, 1y	-1,396.0%	Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y	-1,402.0%	EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y	19.6%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 5y	39.9%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	38.6%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 5y	42.0%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	-15.7%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	27.7%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	41.9%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-10.4%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	13.8%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	20.7%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	0.91x	Current assets / current liabilities.
Quick ratio	0.10x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.10x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	61.3%	Total liabilities / total assets.
Interest coverage	-0.08x	Operating income / interest expense.
Working capital	-$29.7M	Current assets - current liabilities.
Goodwill and intangibles / assets	38.4%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$27.9M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.41x	Revenue / average total assets.
Fixed asset turnover	4.49x	Revenue / average property, plant and equipment.
Inventory turnover	1.91x	Cost of revenue / average inventory.
Days inventory	192 days	365 x average inventory / cost of revenue.
Days payables	238 days	365 x average accounts payable / cost of revenue.
Capex / operating cash flow	11.3%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$0.88	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic	-$0.88	Net income per basic share, as reported (split-adjusted).
Dividends / FCF	0.2%	Dividends paid / free cash flow, when free cash flow is positive.
Buybacks / FCF	2.1%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$23.7M	Share price x shares outstanding.
Enterprise value	-$9.0M	Market cap + total debt - cash - short-term investments.
P/S	0.07x	Market cap / revenue.
P/B	0.09x	Market cap / shareholders' equity. Only when equity is positive.
P/FCF	0.53x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	0.47x	Market cap / cash from operations, when positive.
FCF yield	187.0%	Free cash flow / market cap.
Earnings yield	-234.2%	Net income / market cap (the inverse of P/E).
Dividend yield	0.3%	Dividends paid over the period / market cap.
Shareholder yield	4.2%	(Dividends paid + share buybacks) / market cap.

What was Bioceres Crop Solutions Corp.'s revenue in fiscal 2025?

Bioceres Crop Solutions Corp. reported revenue of $335.1M for fiscal 2025, 27.9% lower than the year before.

Was Bioceres Crop Solutions Corp. profitable in fiscal 2025?

No. It reported a net loss of $55.4M.

How much free cash flow did Bioceres Crop Solutions Corp. generate in fiscal 2025?

Cash from operations of $49.9M minus capital expenditures of $5.6M left free cash flow of $44.3M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Bioceres Crop Solutions Corp.